What is the ROE (Return on Equity) of MacroGenics this year?
The ROE of MacroGenics this year is -0.06 undefined.
MacroGenics ROE 2024
MacroGenics ROE
-0.06
Ticker
MGNX
ISIN
US5560991094
WKN
A1W6ND
In 2024, MacroGenics's return on equity (ROE) was -0.06, a -92.96% increase from the -0.84 ROE in the previous year.
MacroGenics Aktienanalyse
What does MacroGenics do?
MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding MacroGenics's Return on Equity (ROE)
MacroGenics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing MacroGenics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
MacroGenics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in MacroGenics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about MacroGenics stock
How has the Return on Equity (ROE) of MacroGenics developed compared to the previous year?
The ROE of MacroGenics has increased by -92.96% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of MacroGenics?
A high ROE indicates that MacroGenics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of MacroGenics?
A low ROE can indicate that MacroGenics is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of MacroGenics affect the company?
A change in ROE (Return on Equity) of MacroGenics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of MacroGenics?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of MacroGenics?
Some factors that can influence MacroGenics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does MacroGenics pay?
Over the past 12 months, MacroGenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MacroGenics is expected to pay a dividend of 0 USD.
What is the dividend yield of MacroGenics?
The current dividend yield of MacroGenics is .
When does MacroGenics pay dividends?
MacroGenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MacroGenics?
MacroGenics paid dividends every year for the past 0 years.
What is the dividend of MacroGenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MacroGenics located?
MacroGenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von MacroGenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MacroGenics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did MacroGenics pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of MacroGenics in the year 2023?
In the year 2023, MacroGenics distributed 0 USD as dividends.
In which currency does MacroGenics pay out the dividend?
The dividends of MacroGenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MacroGenics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MacroGenics
Our stock analysis for MacroGenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
